Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data
作者: Johannes ClouthAstra M. LiepaGuido MoeserHeiko FriedelMagdalena BernzenJörg TrojanElena Garal-Pantaler
作者单位: 1Medical Affairs, Lilly Deutschland GmbH
2Eli Lilly and Company, Lilly Corporate Center
3masem Research Institute GmbH
4Team Gesundheit GmbH
5Universitätsklinikum Frankfurt
刊名: Health Economics Review, 2018, Vol.8 (1), pp.1-10
来源数据库: Springer Journal
DOI: 10.1186/s13561-018-0199-1
关键词: Hepatocellular carcinomaGermanySecond lineSorafenibHealth economicsGerman statutory health insurance claims data
英文摘要: Abstract(#br) Objective(#br)To estimate both the number of patients with hepatocellular carcinoma (HCC) eligible annually for second-line therapy following sorafenib in Germany and the healthcare costs accrued by patients meeting eligibility criteria.(#br) Methods(#br)Patients with an HCC diagnosis and one or more sorafenib prescription were identified from samples of > 3 million insured persons in each of 2012, 2013 and 2014 using the anonymised Betriebskrankenkasse health insurance scheme database. Incidence rates from 2013 were extrapolated to the German population using data from the statutory health insurance system database and Robert Koch Institute. Resource use and cost data were collected for a subset of patients with follow-up data post-sorafenib.(#br) Results(#br)Between 1032...
全文获取路径: Springer  (合作)
分享到:
来源刊物:

×